Back

Yuhan completes major-market Lazertinib launches as analysts cut price targets

Verifying
  • Yuhan completed major-market launches of Lazertinib and Amivantamab combination therapy.
  • Three API supply contracts were secured by Yuhan this year.
  • Yuhan began building HC-dong in March, targeting operations by 2028.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.
Yuhan completes major-market Lazertinib launches as analysts cut price targets - CoinPost Terminal